Literature DB >> 24703842

IMP3 RNP safe houses prevent miRNA-directed HMGA2 mRNA decay in cancer and development.

Lars Jønson1, Jan Christiansen2, Thomas V O Hansen1, Jonas Vikeså1, Yohei Yamamoto3, Finn C Nielsen4.   

Abstract

The IMP3 RNA-binding protein is associated with metastasis and poor outcome in human cancer. Using solid cancer transcriptome data, we found that IMP3 correlates with HMGA2 mRNA expression. Cytoplasmic IMP3 granules contain HMGA2, and IMP3 dose-dependently increases HMGA2 mRNA. HMGA2 is regulated by let-7, and let-7 antagomiRs make HMGA2 refractory to IMP3. Removal of let-7 target sites eliminates IMP3-dependent stabilization, and IMP3-containing bodies are depleted of Ago1-4 and miRNAs. The relationship between Hmga2 mRNA and IMPs also exists in the developing limb bud, where IMP1-deficient embryos show dose-dependent Hmga2 mRNA downregulation. Finally, IMP3 ribonucleoproteins (RNPs) contain other let-7 target mRNAs, including LIN28B, and a global gene set enrichment analysis demonstrates that miRNA-regulated transcripts in general are upregulated following IMP3 induction. We conclude that IMP3 RNPs may function as cytoplasmic safe houses and prevent miRNA-directed mRNA decay of oncogenes during tumor progression.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24703842     DOI: 10.1016/j.celrep.2014.03.015

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  43 in total

1.  Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis.

Authors:  Douglas Hanniford; Alejandro Ulloa-Morales; Alcida Karz; Maria Gabriela Berzoti-Coelho; Rana S Moubarak; Beatriz Sánchez-Sendra; Andreas Kloetgen; Veronica Davalos; Jochen Imig; Pamela Wu; Varshini Vasudevaraja; Diana Argibay; Karin Lilja; Tommaso Tabaglio; Carlos Monteagudo; Ernesto Guccione; Aristotelis Tsirigos; Iman Osman; Iannis Aifantis; Eva Hernando
Journal:  Cancer Cell       Date:  2020-01-13       Impact factor: 31.743

2.  IMP-3 promotes migration and invasion of melanoma cells by modulating the expression of HMGA2 and predicts poor prognosis in melanoma.

Authors:  Yi-Shuan Sheen; Yi-Hua Liao; Ming-Hsien Lin; Chia-Ying Chu; Bing-Ying Ho; Meng-Chen Hsieh; Pin-Chun Chen; Shih-Ting Cha; Yung-Ming Jeng; Cheng-Chi Chang; Hsien-Ching Chiu; Shiou-Hwa Jee; Min-Liang Kuo; Chia-Yu Chu
Journal:  J Invest Dermatol       Date:  2014-11-07       Impact factor: 8.551

3.  IMP3 promotes stem-like properties in triple-negative breast cancer by regulating SLUG.

Authors:  S Samanta; H Sun; H L Goel; B Pursell; C Chang; A Khan; D L Greiner; S Cao; E Lim; L D Shultz; A M Mercurio
Journal:  Oncogene       Date:  2015-05-18       Impact factor: 9.867

Review 4.  Drug delivery approaches for HuR-targeted therapy for lung cancer.

Authors:  Rajeswari Raguraman; Santny Shanmugarama; Meghna Mehta; Jo Elle Peterson; Yan D Zhao; Anupama Munshi; Rajagopal Ramesh
Journal:  Adv Drug Deliv Rev       Date:  2021-11-22       Impact factor: 15.470

5.  RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation.

Authors:  Jayanth Kumar Palanichamy; Tiffany M Tran; Jonathan M Howard; Jorge R Contreras; Thilini R Fernando; Timothy Sterne-Weiler; Sol Katzman; Masoud Toloue; Weihong Yan; Giuseppe Basso; Martina Pigazzi; Jeremy R Sanford; Dinesh S Rao
Journal:  J Clin Invest       Date:  2016-03-14       Impact factor: 14.808

6.  Oncofetal protein IGF2BP3 facilitates the activity of proto-oncogene protein eIF4E through the destabilization of EIF4E-BP2 mRNA.

Authors:  R Mizutani; N Imamachi; Y Suzuki; H Yoshida; N Tochigi; T Oonishi; Y Suzuki; N Akimitsu
Journal:  Oncogene       Date:  2015-11-02       Impact factor: 9.867

7.  IGF2BP3 Modulates the Interaction of Invasion-Associated Transcripts with RISC.

Authors:  Hanane Ennajdaoui; Jonathan M Howard; Timothy Sterne-Weiler; Fereshteh Jahanbani; Doyle J Coyne; Philip J Uren; Marija Dargyte; Sol Katzman; Jolene M Draper; Andrew Wallace; Oscar Cazarez; Suzanne C Burns; Mei Qiao; Lindsay Hinck; Andrew D Smith; Masoud M Toloue; Benjamin J Blencowe; Luiz O F Penalva; Jeremy R Sanford
Journal:  Cell Rep       Date:  2016-05-19       Impact factor: 9.423

Review 8.  Cancer the'RBP'eutics-RNA-binding proteins as therapeutic targets for cancer.

Authors:  Shakur Mohibi; Xinbin Chen; Jin Zhang
Journal:  Pharmacol Ther       Date:  2019-07-11       Impact factor: 12.310

Review 9.  The biological function of IGF2BPs and their role in tumorigenesis.

Authors:  Qiu-Ying Du; Zhi-Man Zhu; Dong-Sheng Pei
Journal:  Invest New Drugs       Date:  2021-07-12       Impact factor: 3.850

10.  RKIP inhibits gastric cancer cell survival and invasion by regulating the expression of HMGA2 and OPN.

Authors:  Hongyi Liu; Peng Li; Bing Li; Peng Sun; Jiajin Zhang; Baishi Wang; Baoqing Jia
Journal:  Tumour Biol       Date:  2014-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.